Erasca (NASDAQ:ERAS) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Erasca (NASDAQ:ERAS) from a hold rating to a sell rating in a research report report published on Saturday.

ERAS has been the topic of several other research reports. HC Wainwright raised their target price on shares of Erasca from $15.00 to $20.00 and gave the company a “buy” rating in a report on Friday, March 13th. Stifel Nicolaus raised their price objective on shares of Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Morgan Stanley set a $10.00 price objective on shares of Erasca in a report on Monday, January 26th. JPMorgan Chase & Co. raised their price objective on shares of Erasca from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 18th. Finally, Piper Sandler raised their price objective on shares of Erasca from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, March 13th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Erasca Stock Down 1.4%

Shares of NASDAQ:ERAS opened at $10.23 on Friday. The firm’s 50 day moving average price is $15.23 and its 200 day moving average price is $9.57. The stock has a market cap of $3.18 billion, a price-to-earnings ratio of -11.00 and a beta of 0.68. Erasca has a fifty-two week low of $1.06 and a fifty-two week high of $24.28.

Erasca (NASDAQ:ERAS) last issued its earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). On average, equities analysts anticipate that Erasca will post -0.55 EPS for the current year.

Insider Buying and Selling

In other Erasca news, insider Shannon Morris sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $15.04, for a total transaction of $300,800.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Ebun Garner sold 80,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $16.40, for a total transaction of $1,312,000.00. Following the sale, the insider directly owned 25,076 shares in the company, valued at approximately $411,246.40. The trade was a 76.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 14.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Erasca

A number of hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC grew its position in shares of Erasca by 11.3% during the fourth quarter. Neuberger Berman Group LLC now owns 12,358 shares of the company’s stock worth $46,000 after acquiring an additional 1,253 shares during the last quarter. Abel Hall LLC grew its position in shares of Erasca by 8.1% during the first quarter. Abel Hall LLC now owns 16,947 shares of the company’s stock worth $274,000 after acquiring an additional 1,265 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Erasca by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,787 shares of the company’s stock worth $51,000 after acquiring an additional 2,820 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Erasca by 11.1% during the fourth quarter. ProShare Advisors LLC now owns 44,216 shares of the company’s stock worth $164,000 after acquiring an additional 4,430 shares during the last quarter. Finally, KBC Group NV purchased a new position in shares of Erasca during the first quarter worth approximately $81,000. 67.78% of the stock is currently owned by hedge funds and other institutional investors.

Erasca News Summary

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $20 price target on Erasca, indicating the firm still sees meaningful upside even after trimming near- and long-term EPS estimates.
• Positive Sentiment: Piper Sandler also remained positive on Erasca, another signal that some analysts continue to back the stock after recent volatility. Article Title
• Neutral Sentiment: Erasca was mentioned in a transcript from its presentation at the Bank of America Global Healthcare Conference 2026, which may keep investor attention on the company’s pipeline and strategy, but no major new catalyst was highlighted. Article Title
• Negative Sentiment: Multiple law firms, including Pomerantz, Kirby McInerney, and Bragar Eagel & Squire, announced investigations or shareholder alerts regarding possible securities-law violations at Erasca, which can weigh on sentiment and raise litigation concerns. Article Title
• Negative Sentiment: HC Wainwright cut EPS estimates for FY2026 through FY2030, reflecting a more cautious view on Erasca’s earnings trajectory after the company’s recent quarterly miss, which may be pressuring the stock.
• Negative Sentiment: A separate article highlighted that a hedge fund added to its Erasca position after the stock had already run sharply higher, which can reinforce concerns that some of the good news may already be priced in. Article Title

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.